ReviewFrontiers in pediatrics2018
The Vasculopathy of Juvenile Dermatomyositis.
Review in Frontiers in pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 75 citations in OpenAlex.
- Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary centre.Rheumatology (Oxford, England) · 2026Article
- Clinical features, triggers, and risk factors of severe gastrointestinal involvement in anti-NXP2-positive juvenile dermatomyositis: a retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Impact of Juvenile Dermatomyositis on Growth, Puberty, Bone Mineral Density, and Body Composition in Children.Mediterranean journal of rheumatology · 2026Review
- Severe Juvenile Dermatomyositis With Peripheral Nervous System Involvement: A Case Report.Cureus · 2026Article
- Juvenile dermatomyositis: new insights into pathogenesis and clinical applications.Pediatric rheumatology online journal · 2025Review
- Ulcerated Gottron Papules and Sign Along with Degos-Like Lesions in Dermatomyositis: A Prognostic Marker?Indian dermatology online journal · 2025Article
- CD68 + macrophage infiltrations in muscle tissue of juvenile dermatomyositis associated with the course of the disease, not with the severity.Clinical rheumatology · 2025Article
- CAR T cell therapy for children with rheumatic disease: the time is now.Nature reviews. Rheumatology · 2025Review
- Monozygotic twins discordant for juvenile dermatomyositis: clinical, serological and gene expression studies.Pediatric rheumatology online journal · 2025Article
- The emerging role of growth differentiation factor 15 as a potential disease biomarker in juvenile dermatomyositis.Rheumatology (Oxford, England) · 2025Article
- Article
- [Cutaneous ulceration in dermatomyositis : Case reports with positive anti-NXP-2/anti-TIF1-gamma antibody status].Dermatologie (Heidelberg, Germany) · 2025Article
- The Role of Pyroptosis-Related Gene Signature and Immune Infiltration in Juvenile Dermatomyositis.Clinical, cosmetic and investigational dermatology · 2025Article
- Anesthetic Challenges in Laparoscopic Surgery for a Child with Juvenile Dermatomyositis.Cureus · 2024Article
- Unveiling Cardiac Involvement in Juvenile Dermatomyositis Through Speckle-Tracking Echocardiography.Pediatric cardiology · 2024Article
- Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.Pediatric rheumatology online journal · 2024Article
- Childhood Cerebral Vasculitis : A Multidisciplinary Approach.Clinical neuroradiology · 2023Review
- Adipose tissue distribution is associated with cardio-metabolic alterations in adult patients with juvenile-onset dermatomyositis.Rheumatology (Oxford, England) · 2023Article
- Juvenile dermatomyositis and nephrotic syndrome: A case report and a mini literature review.Frontiers in pediatrics · 2023Article
- Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis.Current rheumatology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile dermatomyositis (JDM) is a rare autoimmune disease mainly characterized by muscle and skin involvement. Vasculopathy is considered central to the pathogenesis of the disease. The exact nature of vasculopathy is not yet understood but it is a complex process with both an inflammatory and a non-inflammatory, occlusive component. Impaired function of JDM vasculature includes immune complex deposition, altered expression of cell adhesion molecules predominantly inducing Th17 cell infiltration, and endothelial cell dysfunction. Development of vasculopathy is associated with the severe extra-muscular manifestations of JDM, such as gastrointestinal and cardiac manifestations, interstitial lung disease, ulcerative skin disease or development of calcinosis, and portends a poor prognosis. Correlation of histopathological findings, autoantibodies, and extensive diagnostic workup represent key elements to the early detection of vasculopathic features and early aggressive treatment. Monitoring of vasculopathy remains challenging due to the lack of non-invasive biomarkers. Current treatment approaches provide variable benefit, but better understanding of the essential pathogenic mechanisms should help lead to improved outcomes. Whilst acknowledging that evidence is limited, this review aims to describe the vasculopathy of JDM in the context of pathophysiology, clinical features, and treatment of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.